Adding TKIs Could Increase Responses in Metastatic HER2+ Breast Cancer

A laboratory study found that combining anti-HER2 TKIs with trastuzumab and pertuzumab can result in enhanced anticancer activity in HER2+ breast cancer cell lines.

Source: CancerNetwork - August 7, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news